Pluristem Therapeutics Inc.Find Ratings Reports
PLURISTEM THERAPEUTICS INC's gross profit margin for the third quarter of its fiscal year 2018 has significantly increased when compared to the same period a year ago. Sales have remained unchanged, but net income increased.
During the same period, stockholders' equity ("net worth") has decreased by 6.72% from the same quarter last year.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY18||Q3 FY17|
|Net Sales ($mil)||0.0||0.0|
|Net Income ($mil)||-1.53||-7.86|
|Balance Sheet||Q3 FY18||Q3 FY17|
|Cash & Equiv. ($mil)||34.07||33.06|
|Total Assets ($mil)||42.97||43.54|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q3 FY18||Q3 FY17|
|Gross Profit Margin||0.0||0.0|
|Return on Assets||-56.22||-62.02|
|Return on Equity||-72.71||-75.8|
|Debt||Q3 FY18||Q3 FY17|
|Share Data||Q3 FY18||Q3 FY17|
|Shares outstanding (mil)||110.87||96.17|
|Div / share||0.0||0.0|
|Book value / share||0.3||0.37|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||572108.0||285581.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Conducting a second comparison, its price-to-book ratio of 4.20 indicates a premium versus the S&P 500 average of 3.29 and a significant discount versus the industry average of 14.33. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. The valuation analysis reveals that, PLURISTEM THERAPEUTICS INC seems to be trading at a premium to investment alternatives within the industry.
|PSTI NM||Peers 40.64||PSTI NM||Peers 50.79|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
PSTI's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
PSTI's P/CF is negative making the measure meaningless.
|PSTI NM||Peers 30.43||PSTI NA||Peers 0.39|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
PSTI's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|PSTI 4.20||Peers 14.33||PSTI 27.28||Peers 27.58|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
PSTI is trading at a significant discount to its peers.
Average. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
PSTI is expected to keep pace with its peers on the basis of earnings growth.
|PSTI 2793.87||Peers 72.30||PSTI NA||Peers 339.57|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
PSTI is trading at a significant premium to its industry.
Neutral. Comparing a company's sales growth to its industry helps to determine if the company is adding or losing market share.
The growth rate for PSTI is not available.